Navigation Links
Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
Date:3/20/2008

VANCOUVER, March 20 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, is scheduled to participate in the Credit Suisse Global Leveraged Finance Conference, which is being held March 24-27 in Phoenix, Arizona.

Mr. Thomas Bailey, Angiotech's Chief Financial Officer, is scheduled to present on Wednesday, March 26, beginning at approximately 8:00 am Mountain Time. A question and answer session will immediately follow the presentation.

Presentations at this conference will not be webcast. More information is available on the Angiotech website (http://www.angiotech.com) under the Investors section.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Deirdre Neary, Manager, Investor Relations, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
2. Angiotech to participate in Lehman Brothers Healthcare Conference
3. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
4. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
5. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
6. Angiotech announces results for the fourth quarter ended December 31, 2007
7. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. Angiotech and Symphony Medical Announce Licensing Agreement
10. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
11. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines and segments ... revenue. The Automatic patient billing market in Asia is ... at a developing CAGR of 7.2% from 2013 to ... Automatic patient billing market, to get an idea of ... of the segmentation of this market in the same ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems ... analysis and forecast of revenue. The Orthopedic braces and support ... $416.5 million by 2018, at a developing CAGR of 4.4% ... the Asian Orthopedic braces and support systems market, to get ... a glimpse of the segmentation of orthopedic braces and support ...
(Date:10/18/2014)... The “Human Insulin Market- by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... Kevin W. Sharer, chairman and chief executive officer of Amgen ... plan to retire from the Company at the end of ... an orderly transition process, Sharer will step down as CEO ... Company,s Board of Directors until December 31, 2012, at which ...
... OAKS, Calif., Dec. 15, 2011  Amgen (NASDAQ: AMGN ... $0.36 per share dividend for the first quarter of 2012. ... the previous two quarters. The dividend will be paid on ... the close of business on Feb. 15, 2012.  ...
... 15, 2011 Prolong Pharmaceuticals today announced ... spearhead the firms, engineering and facilities planning ...   Having previously directed the construction of the ... Grange Castle facility in Dublin, Ireland, Flachmeyer is ...
Cached Biology Technology:Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 3Amgen Announces 2012 First Quarter Dividend 2Amgen Announces 2012 First Quarter Dividend 3Prolong's Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran 2
(Date:10/18/2014)... of patients with undiagnosed, suspected genetic conditions, a certain ... higher molecular diagnostic yield than traditional molecular diagnostic methods, ... The study is being released to coincide with the ... sequencing, which sequences the protein­coding region of the genome ... in a cell or organism), has been rapidly applied ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2New perspectives for development of an RSV vaccine 2
... National Oceanic and Atmospheric Administration, and the co-trustees for ... announced today they have started the injury assessment and ... a legal process to determine the type and amount ... to natural resources and their human uses as a ...
... Troy, N.Y. The purification of drug components ... is particularly true of drugs that utilize proteins, which ... impurities. Scientists within the Center for Biotechnology and Interdisciplinary ... magnetic resonance (NMR) to understand and improve an important ...
... The National Institute of Neurological Disorders and Stroke (NINDS), ... two new sites as part of the Morris K. Udall ... grants will provide a five-year investment totaling more than $16 ... for Medical Research in Manhasset, N.Y. NINDS ...
Cached Biology News:Resource restoration planning process begins for BP/Deepwater Horizon oil spill 2Resource restoration planning process begins for BP/Deepwater Horizon oil spill 3Purifying proteins: Rensselaer researchers use NMR to improve drug development 2Purifying proteins: Rensselaer researchers use NMR to improve drug development 3NINDS awards new Udall Centers for Parkinson's Disease Research 2NINDS awards new Udall Centers for Parkinson's Disease Research 3